HIV care using differentiated service delivery during the COVID‐19 pandemic: a nationwide cohort study in the US Department of Veterans AffairsCOVID-19 전염병 동안 차별화된 서비스 전달을 사용한 HIV 치료: 미국 재향 군인국의 전국 코호트 연구Supplement: Research Article Published on 2021-10-282022-09-10 Journal: Journal of the International AIDS Society [Category] MERS, SARS, 치료기술, [키워드] Affair aging antiretroviral ARV Care change clinic visit Clinic visits cohort study Coverage COVID‐19 COVID‐19 Department detectable determine disease enrolled evaluate except for extended refills Health healthcare HIV impacted Infectious disease less medication men Most patient Most patients not disrupted pandemic Patient people with HIV Result RNA rural areas suppressed The United States United States veteran veterans Viral Viral load virtual visits VL test VL testing women [DOI] 10.1002/jia2.25810 PMC 바로가기 [Article Type] Supplement: Research Article
Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) dataResearch article Published on 2021-10-152022-10-05 Journal: The Lancet. HIV [Category] SARS, 임상, [키워드] 95% CI added adjusted adjusted odds ratio Adults Advancing African American Analysis association black CD4 cell Cell center Clinical severity Community Comorbidities covariates COVID COVID-19 COVID-19 case COVID-19 cases COVID-19 disease severity COVID-19 pandemic death demographic characteristics Effect elevated encounter evidence of exacerbating finding funding groups health condition health inequities health-care health-care system higher odd Hispanic HIV HIV infection hospitalisation immunodeficiency Inconclusive individual Infectious diseases information Latinx male marker Mild Moderate COVID-19 Mortality obesity occurred Older age outcome outcomes people with HIV population level Prevent public health reduced Regression model risk smoking Support USA Viral load with HIV [DOI] 10.1016/S2352-3018(21)00239-3 [Article Type] Research article
Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational StudyOnline Only Articles Published on 2021-10-012022-10-31 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID-19, MERS, SARS, [키워드] 95% CI 95% confidence interval acquisition adjusted hazard ratio age Analysis Antiretroviral therapy association C-reactive protein CCP Characteristics characterization clinical Comorbidities coronavirus disease COVID-19 Cox regression cumulative defined disease severity excluded group higher risk HIV HIV infection HIV-negative hospital Hospitalized Human Human immunodeficiency virus hypoxia increased mortality increased risk ISARIC Kaplan-Meier method Lymphocyte count median modulate Mortality other variable outcome Oxygen therapy patients patients hospitalized people with HIV Prospective respiratory Result SARS-CoV-2 Sex systemic symptom United Kingdom WHO with COVID-19 World Health Organization [DOI] 10.1093/cid/ciaa1605 PMC 바로가기 [Article Type] Online Only Articles
Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study남아프리카의 높은 HIV 및 결핵 유병률 환경에서 COVID-19 관련 병원 내 사망률의 위험 요소: 코호트 연구Article Published on 2021-09-012022-09-11 Journal: The Lancet. HIV [Category] SARS, 치료제, [키워드] 95% CI adjusted odds ratio African age Antiretroviral therapy ART Asthma available data benefit cardiac disease cause chronic cardiac disease chronic pulmonary disease chronic renal disease cohort study Comorbidities Comorbidity country COVID-19 death defined described diabete diabetes died discharge discharged Ethnicity excluded Factor Factors high risk HIV HIV infection HIV-uninfected hospital Hospital admissions Hospital mortality Hospital stay hypertension In-hospital in-hospital mortality Increasing increasing age individual individuals Infectious disease Interaction laboratory-confirmed SARS-CoV-2 infection male Male sex malignancy Missing data MOST multiple imputation multivariable logistic regression multivariable logistic regression models National non-communicable diseases number of comorbidity occurred Older Other outcome past Patient patients with COVID-19 people with HIV Prevalence public health random-effect renal disease reported risk risk factor Risk factors SARS-COV-2 infection Sex South South Africa submitted Surveillance Treatment Tuberculosis used data Vaccine was used were used [DOI] 10.1016/S2352-3018(21)00151-X PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial남아프리카에 HIV가 있거나없는 사람들의 SARS-COV-2에 대한 Chadox1 NCOV-19 (AZD1222) 백신의 안전성 및 면역 원성 : 무작위, 이중 맹검, 위약 대조, Phase 1B/2A 시험의 중간 분석Clinical Trial Published on 2021-08-172022-08-13 Journal: The Lancet. HIV [Category] MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 1B/2A trial 95% CI adverse event adverse events African Alanine alanine aminotranferase allocation concealment Antibody Response Antibody Units Antiretroviral therapy Asp614Gly wild-type AZD1222 B.1.351 baseline Beta Beta variant binding antibodies binding antibody unit booster booster response both groups ChAdOx1 ChAdOx1 nCov 19 ChAdOx1 nCoV-19 clinical COV005 criteria cross-reactive binding antibodies cross-reactive binding antibody cross-reactivity D614G demonstrated died domain dose double-blind elevated eligibility criteria enrolled enrolment Fever finding FIVE foundation full-length funding geometric mean geometric mean concentration GMC high responder high responders High-level binding antibody HIV HIV-negative hospital IgG responses immunogenicity in both groups increased risk individual individuals Innovation interim analysis Intervention less Medical Research Council Melinda Gate Melinda Gates n=36 nCoV neutralisation Neutralising activity outcome Pan participant Participants people with HIV person with HIV Placebo placebo-controlled plasma Primary immunogenicity analyses Primary immunogenicity analysis prime-boost regimen priming priming dose randomised Randomly reactogenicity receive Receptor-binding domain Registered registry responses responses against retained rising Safety SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens Serious Adverse Events seronegative seropositive serum IgG Seven severe COVID-19 South South Africa titre Trial unlikely Vaccine vaccine dose Viral Viral load wild-type wild-type Wuhan-1 Asp614Gly with HIV [DOI] 10.1016/S2352-3018(21)00157-0 PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2 percent positivity and risk factors among people with HIV at an urban academic medical centerResearch Article Published on 2021-07-212022-10-28 Journal: PLoS ONE [Category] COVID-19, SARS, [키워드] 95% CI Antiretroviral therapy ART black calculated CD4 T-cell chronic disease Chronic diseases clinical factors collected Comorbidities conducted COVID-19 pandemic cross-sectional Demographic factors demographic group determine Diagnosis difference higher risk Hispanic Hispanic/Latino ethnicity HIV ICD-10 identify Infection Latino Logistic regression male multivariate no significant difference Patient people with HIV positive Presence regimen risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR testing SARS-CoV-2 positivity significantly more tested Viral load Wilcoxon rank sum [DOI] 10.1371/journal.pone.0254994 PMC 바로가기 [Article Type] Research Article
Impact of the COVID-19 pandemic on HIV care in GuatemalaResearch article Published on 2021-07-012022-10-05 Journal: International Journal of Infectious Diseases [Category] SARS, 진단, [키워드] 95% CI affected Angel average Care clinical Comparative analysis conducted confidence interval coronavirus disease COVID-19 COVID-19 pandemic death Diagnosis diagnostic healthcare Healthcare attention HIV HIV testing Human immunodeficiency virus Impact Laboratory Luis objective opportunistic infection opportunistic Infections pandemic people with HIV performed provide reduce reduction Result Retrospective study [DOI] 10.1016/j.ijid.2021.06.011 [Article Type] Research article
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trialHIV 감염에서 SARS-COV-2에 대한 Chadox1 NCOV-19 (AZD1222) 백신의 안전성 및 면역 원성 : 2/3 상 임상 시험의 단일 암 보체.Clinical Trial Published on 2021-06-182022-08-13 Journal: The Lancet. HIV [Category] MERS, SARS, 임상, 진단, [키워드] ACHE age All participants analysed analyses anti-Spike IgG anti-spike IgG response Anti-spike IgG responses antibody Antiretroviral therapy ART AstraZeneca available data AZD1222 CD4 CD4 cell CD4 count CD4 counts Cell cell-mediated immune response Cell-mediated immune responses cellular response Cellular responses ChAdOx1 ChAdOx1 nCoV-19 chill chills Clinical research clinical trial Coalition Comorbidity determined by dose Eligible participants ELISA ELISPOT enrolled enrolment enzyme enzyme-linked immunospot assay fatigue finding FIVE frequencies Frequency functional funding General population headache HIV HIV clinics HIV-negative HIV-uninfected humoral Humoral response humoral responses IFN-γ IgG response IgG responses immune responses Immunity immunogenic immunogenicity injection injection site Innovation IQR joint joint pain less Live virus Local London magnitude malaise male median median age muscle ache nausea network neutralisation NIHR NIHR Oxford Biomedical Research Centre no correlation no difference occurred Open-label outcome Oxford Pain participant Participants peaked people with HIV persistence phase 2/3 phase 2/3 trial plasma Primary outcome Primary outcomes prime-boost regimen proliferation proliferative protocol reactogenicity Registered reported required response Safe Safety SARS-CoV-2 SARS-CoV-2 spike-specific Serious Adverse Event Serious Adverse Events single-arm South sustained systemic reaction systemic reactions T-cell the vaccine undetectable vaccination Vaccine vaccine immunogenicity Valley Viral Viral load were measured with HIV [DOI] 10.1016/S2352-3018(21)00103-X PMC 바로가기 [Article Type] Clinical Trial
Turning threats into opportunities: how to implement and advance quality TB services for people with HIV during the COVID‐19 pandemic and beyondCommentary Published on 2021-03-312022-10-31 Journal: Journal of the International AIDS Society [Category] COVID-19, MERS, SARS, [키워드] accelerate affected affecting AIDS approach can be used Care children Community COVID‐19 COVID‐19 Diagnosis differentiated service delivery Diseases Guidance health system healthcare services help HIV implementation IMPROVE Infectious disease Innovation integration lack maintain medication Model MOST pandemic people affected by TB people with HIV public health threat released Research Stigma supported target threat Treatment Tuberculosis Turning [DOI] 10.1002/jia2.25696 PMC 바로가기 [Article Type] Commentary
Impact of a COVID-19 National Lockdown on Integrated Care for Hypertension and HIVCOVID-19 국가 봉쇄가 고혈압 및 HIV 통합 치료에 미치는 영향Original Research Published on 2021-02-042022-09-11 Journal: Global Heart [Category] MERS, 치료제, [키워드] Access to care access to medicines anticipated antiretroviral Antiretrovirals chronic condition chronic conditions Clinical outcome clinical outcomes Cohort COVID-19 evaluate Government health facilities HIV HIV clinics hypertension Impact limit lockdown lockdowns measure Medicine Medicines motor vehicle offered open outcome Patient people with HIV public health remained reported spread of COVID-19 Uganda [DOI] 10.5334/gh.928 PMC 바로가기 [Article Type] Original Research